For four years the United States government said almost nothing. The illness killing gay men, hemophiliacs, and people who used drugs had no funding, no urgency, and — until 1982 — no official name. It went on to kill tens of millions, reshape queer politics, drug pricing, and public health itself, and became the first modern pandemic in which patients organized to save their own lives.
HIV is not evenly shared either. Sub-Saharan Africa carries the overwhelming majority of the global burden, while new infections are rising fastest in Eastern Europe, Central Asia, Latin America, and parts of the Asia-Pacific. Circles are scaled to estimated people living with HIV.
The interactive map could not load. The highest-burden countries — South Africa, India, Mozambique, Nigeria, Tanzania, Kenya, Uganda, and Zambia — remain listed below.
The first cases looked like nothing anyone had seen: young, otherwise healthy gay men dying of infections that shouldn’t have been able to kill them. The press called it “gay cancer.” The CDC called it GRID — Gay-Related Immune Deficiency. Reagan didn’t say the word “AIDS” publicly until 1985, four years and roughly 12,000 American deaths into the epidemic.
Patients did not wait for institutions to act. ACT UP turned die-ins into policy change; the FDA’s drug-approval process was rebuilt under pressure from the people it was failing. Triple-combination therapy arrived in 1996 and turned a death sentence into a chronic condition — for anyone who could reach it. Twenty years later, the science confirmed what activists had insisted for a decade: undetectable equals untransmittable.
A blood sample drawn in Léopoldville, Belgian Congo, later tests positive for HIV-1 — the earliest confirmed infection, decades before anyone knew to look.
The CDC reports a rare pneumonia in five previously healthy gay men in Los Angeles. Within months, clusters of rare cancers and infections appear in New York and San Francisco.
The CDC adopts the term Acquired Immunodeficiency Syndrome, retiring the stigmatizing “GRID.” The name doesn’t slow the epidemic — or the silence around it.
Françoise Barré-Sinoussi and Luc Montagnier at the Pasteur Institute isolate the virus that causes AIDS — later named HIV. They share the 2008 Nobel Prize for the discovery.
The FDA approves the first HIV antibody test, letting blood banks screen the supply — three years after transfusion-linked cases were first reported.
AZT becomes the first approved antiretroviral, but as monotherapy it buys months, not years. The same year, ACT UP forms in New York, turning grief into direct action for faster drug approval.
Trial 076 shows AZT given during pregnancy and delivery cuts mother-to-child transmission by roughly two-thirds — the first proof the epidemic’s path could be blocked.
AIDS becomes the leading cause of death for Americans aged 25–44. Tens of thousands die that year alone, most having lived to see no effective treatment.
Protease inhibitors combined with existing drugs — HAART — suppress the virus for the first time. U.S. AIDS deaths fall by more than 40% within a year. For those with access, a death sentence becomes a chronic disease.
The WTO affirms that public health can override patent protection, opening the door to affordable generic antiretrovirals across the developing world.
The U.S. President’s Emergency Plan for AIDS Relief becomes the largest global-health initiative ever committed to a single disease, funding treatment across dozens of countries.
Timothy Ray Brown becomes the first person cured of HIV, after a stem-cell transplant for leukemia from a donor with a rare HIV-resistant gene mutation.
The FDA approves daily Truvada as pre-exposure prophylaxis — the first pill shown to prevent HIV infection in people who don’t yet have it.
Large clinical studies find zero linked transmissions from partners with a sustained undetectable viral load — turning a decade of activist claims into medical consensus.
Cabenuva is approved — a shot every one to two months replaces a daily pill for viral suppression, easing one of treatment’s hardest daily burdens.
Trials of lenacapavir, a prevention injection given just twice a year, report near-total protection — the closest the field has come to a functional vaccine.
Every person who reaches the next step effectively stops transmitting the virus. Every person who doesn’t is where the epidemic still lives. UNAIDS tracks this as “95-95-95” — the world isn’t there yet. Hover a step to read it.
For years, President Thabo Mbeki’s government publicly questioned whether HIV caused AIDS at all, restricted access to antiretroviral drugs — including nevirapine, which could have halved mother-to-child transmission for the cost of a single dose — and gave a public platform to unproven remedies instead. A 2008 Harvard study estimated the resulting delay caused more than 330,000 preventable deaths and left tens of thousands of infants born with HIV who could have been protected.
It was not a failure of medicine. Triple therapy already existed, already worked, and was already saving lives elsewhere in the world. It was a failure of the people who decide who gets it — a reminder that a treatable disease can still kill at the scale of an untreatable one, if the people in charge decide it should.
A person dies of an entirely treatable disease roughly every fifty seconds — not because the drugs don’t exist, but because access, stigma, and funding decide who receives them. HIV did not turn itself into a survivable, chronic condition; medicine and the people who refused to wait for it did. Whether it stays that way for everyone is a choice, not a discovery.
Figures are approximate, drawn from UNAIDS Global HIV/AIDS statistics and published epidemiological studies. Verify against UNAIDS and national programmes before operational use.